CPMS manages preclinical safety studies in China on behalf of Western biopharmaceutical companies. We combine Chinese domestic expertise with Western compliance processes and oversee each stage of IND-enabling drug development.

Ernest D Bush, PhD
CPMS Managing Director  

Q:  How is China positioned today in the GLP CRO industry?

A:  2008 was a watershed year for the preclinical services sector in China. First, several major Western >> 

Q:  Are lower costs in China a key motivating factor?

A:  Sponsors can expect for an identical set of preclinical studies, a 35-50% savings versus >> 

Q:  How close is the Chinese GLP preclinical services sector to reaching a level of quality and compliance equal to a typical Western CRO?

A:  An interesting question, and probably the question I am most often asked by companies considering >> 

Q:  Why is the preclinical services sector in China of strategic interest to the West?

A:  The key driver is usually cost. If a sponsor can save 35 – 50% on a preclinical IND-enabling >> 

Q:  What recommendations do you have for sponsors interested in sending their preclinical studies to China?

A:  This is a complicated question and my response would normally be dependent on the specific >>